טוען...
Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis
Administration of bevacizumab to patients with brain metastases (BM) is controversial due to concerns about the increased risk of intracranial hemorrhage (ICH). This meta-analysis assessed whether the risk of ICH increases in BM patients receiving treatments that contain bevacizumab versus without....
שמור ב:
| הוצא לאור ב: | J Neurooncol |
|---|---|
| Main Authors: | , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Springer US
2017
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5846997/ https://ncbi.nlm.nih.gov/pubmed/29170906 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11060-017-2693-4 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|